We were founded on 1 October 1896 by Fritz Hoffman - La Roche, one of the first to realize that the industrial production of standard medicines would be an important advantage in combating diseases.
Our visionary founder, Fritz Hoffman – La Roche, led the company to become an innovation-oriented and international company, starting from the first moment it was founded. Our presence on multinational platforms gives us the opportunity to recognize the needs in every region of the world and to offer our health solutions.
We make discoveries for our common future
As a research-based company providing healthcare services, we discover, develop, and offer products and services that can provide significant benefits to patients and healthcare professionals. This spectrum ranges from early diagnosis of diseases to prevention, diagnosis, treatment, and post-treatment follow-up. Today, we employ around 81,000 people and sell our products in 139 countries.
Innovation throughout the health spectrum
In order to provide maximum benefit for patients, we maintain an integrated innovation approach throughout the healthcare system, from early diagnosis to disease prevention, diagnosis, treatment and follow-up. These areas will be linked with each other naturally, being integrated in a way that will provide patients with more effective, safer and more cost-effective health care services.
Products with clinical benefits
As Roche, we have allocated our resources to two areas of intensive research such as pharmaceuticals and diagnostics. Among these activities, we give priority to areas with unmet medical needs. The aim is to offer new and improved medicines, diagnostic methods, and services that are not provided by currently available options yet. For this reason, our intense investment in research and development, such as CHF 9.9 billion in 2009, will continue in the future.
The main areas of activity of Roche, which acts with the mission of "creating, producing and offering high-quality solutions for unresolved health problems", are pharmaceuticals and diagnostics, and it offers services in the same areas in Turkey.
Starting its journey in Turkey in 1958, Roche Pharmaceuticals offers innovative solutions to Turkish physicians and patients at the same time with the rest of the world with its unique products for the treatment of diseases in the fields of oncology, hematology, virology, dialysis, transplantation, rheumatology, and osteoporosis.
In the light of Roche's global expertise and experience, with the goal of becoming one of the leading healthcare companies in Turkey, Roche Diagnostics Turkey improves patients' lives since 1991 with innovative equipment for professional and personal use and for biochemistry, hormones, genetic, molecular and cancer testing portfolio in the fields of Centralized and Point of Care Solutions, Molecular Diagnostics and Diabetes Care.
As it has done so far, Roche will continue to increase the quality of health and life in Turkey with its global approach and local creative solutions.
Where we are today
Focuses on two main areas of Pharmaceuticals and Diagnostics, Roche is one of the world's leading companies providing healthcare services.
Serving Patients and Customers
Roche's primary purpose is to identify and meet the needs of patients and customers, which includes being in close contact with patients and customers, being able to find solutions to their problems by listening to what they say and even anticipating their future needs.
As Roche, we are focused on two areas of Pharmaceuticals and Diagnostics which involve intense research. Among our corporate activities, we prioritize areas where we know that we can make a difference with our experience and where there are unmet needs. Our goal is to create new medicines, diagnostic methods, and services that can offer significant benefits beyond existing options.
What we mean by innovation is the creation and commercialization of medically differentiated products and services that will bring healing touches to add health, quality, and time to patients' lives.
As a research-oriented company, we benefit from the latest technologies and the latest discoveries while developing our products.
Owing to all of these aspects,
· In 2009, Roche devoted more resources to research and development than to sales and marketing.
· Roche continues its tradition of being in partnership with some of the world's most forward-looking and technologically advanced companies.
· Roche invests heavily in biotechnology and is the world's largest biotechnology company.
Where we are heading to
Two patients diagnosed with the same disease may react differently to the same drug. While one patient may benefit from the treatment administered, another may suffer from the undesirable side effects of the drug rather than seeing the desired clinical results. Some of these differences may be due to genetic and other biological differences between patients. The underlying idea of Personalized Treatment is to evaluate these differences at the molecular level and to develop boutique treatment methods suitable for the needs of certain patient groups. This approach has enormous potential for healthcare to be better, safer, and more cost-effective.
Even though a little more time is required to reach the full potential, the healthcare market is visibly moving away from “one size fits all” products. Continuing to be a driving force behind this approach, Roche still has many Personalized Therapy products that have been put on the market. An important benefit of the personalization of pharmaceuticals lies in the interaction of medication and diagnosis. Being the market leader in both fields gives us an important competitive advantage in terms of constituting a solution to the health problems of the future.